AVT

Alvotech is a global biopharmaceutical company specialized in the development and manufacture of high-quality biosimilar medicines for patients worldwide. Headquartered in Iceland, the company utilizes a vertically integrated platform that encompasses the entire biosimilar lifecycle, from cell line development and process design to large-scale manufacturing and commercialization. Alvotech's portfolio targets major therapeutic areas including immunology, oncology, ophthalmology, and bone health, aiming to increase patient access to affordable biologic treatments. Its lead product, Simlandi (AVT02), is a high-concentration, interchangeable biosimilar to Humira that has received regulatory approval in multiple global markets, including the United States and Europe. Through strategic partnerships with leading pharmaceutical firms, Alvotech is positioned as a significant player in the rapidly expanding global biosimilars landscape.